Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TELA Bio, Inc. (TELA : NSDQ)

• Company Description    TELA Bio Inc. is a commercial stage medical technology company. It is focused on the designing, developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a portfolio of advanced reinforced tissue matrices. TELA Bio Inc. is headquartered in Malvern, Pennsylvania. Number of Employees: 209

• Price / Volume Information    Yesterday's Closing Price: $1.15 Daily Weekly Monthly 20 Day Moving Average: 351,209 shares Shares Outstanding: 40.34 (millions) Market Capitalization: $46.39 (millions) Beta: 0.87 52 Week High: $3.10 52 Week Low: $0.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.60% 2.24% 12 Week -27.67% -29.74% Year To Date -61.92% -68.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1 GREAT VALLEY PARKWAY SUITE 24 - MALVERN,PA 19355 USA ph: 484-320-2930 fax: - ir@telabio.com http://www.telabio.com

• General Corporate Information    Officers Antony Koblish - President; Chief Executive Officer and Director Doug Evans - Chairman; Board of Directors Roberto Cuca - Chief Operating Officer and Chief Financial Office Megan Smeykal - Chief Accounting Officer and Controller Kurt Azarbarzin - Director Peer Information TELA Bio, Inc. (CORR.) TELA Bio, Inc. (RSPI) TELA Bio, Inc. (CGXP) TELA Bio, Inc. (BGEN) TELA Bio, Inc. (GTBP) TELA Bio, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 872381108 SIC: 3841 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 40.34 Most Recent Split Date: (:1) Beta: 0.87 Market Capitalization: $46.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.18 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.84 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 29.26 Price/Cash Flow: - Price / Sales: 0.60 EPS Growth vs. Year Ago Period: 54.76% vs. Previous Quarter: 13.64% Sales Growth vs. Year Ago Period: 9.14% vs. Previous Quarter: 2.44% ROE 09/30/25 - -272.13 06/30/25 - -329.48 03/31/25 - -402.45 ROA 09/30/25 - -53.25 06/30/25 - -57.34 03/31/25 - -62.73 Current Ratio 09/30/25 - 3.30 06/30/25 - 3.19 03/31/25 - 4.22 Quick Ratio 09/30/25 - 2.62 06/30/25 - 2.59 03/31/25 - 3.40 Operating Margin 09/30/25 - -50.61 06/30/25 - -54.12 03/31/25 - -61.00 Net Margin 09/30/25 - -50.61 06/30/25 - -54.12 03/31/25 - -61.00 Pre-Tax Margin 09/30/25 - -50.69 06/30/25 - -54.20 03/31/25 - -61.13 Book Value 09/30/25 - 0.04 06/30/25 - 0.23 03/31/25 - 0.46 Inventory Turnover 09/30/25 - 2.02 06/30/25 - 1.89 03/31/25 - 1.74 Debt-to-Equity 09/30/25 - 26.65 06/30/25 - 4.14 03/31/25 - 2.28 Debt-to-Capital 09/30/25 - 96.38 06/30/25 - 80.56 03/31/25 - 69.49

Powered by Zacks Investment Research ©